Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Vivos Therapeutics (VVOS) Gross Margin (2020 - 2025)

Vivos Therapeutics has reported Gross Margin over the past 6 years, most recently at 78.14% for Q4 2025.

  • Quarterly Gross Margin rose 2143.0% to 78.14% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 60.45% through Dec 2025, up 45.0% year-over-year, with the annual reading at 60.44% for FY2025, 43.0% up from the prior year.
  • Gross Margin was 78.14% for Q4 2025 at Vivos Therapeutics, up from 58.04% in the prior quarter.
  • Over five years, Gross Margin peaked at 80.59% in Q2 2021 and troughed at 50.03% in Q1 2025.
  • The 5-year median for Gross Margin is 61.19% (2023), against an average of 63.53%.
  • Year-over-year, Gross Margin crashed -1873bps in 2022 and then soared 2143bps in 2025.
  • A 5-year view of Gross Margin shows it stood at 70.71% in 2021, then fell by -15bps to 60.35% in 2022, then increased by 7bps to 64.32% in 2023, then fell by -12bps to 56.71% in 2024, then soared by 38bps to 78.14% in 2025.
  • Per Business Quant, the three most recent readings for VVOS's Gross Margin are 78.14% (Q4 2025), 58.04% (Q3 2025), and 55.24% (Q2 2025).